Symbols

CNTG(Delisted)

Centogene·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CNTG

Centogene N.V.

A commercial-stage essential biodata life science partner for rare and neurodegenerative diseases

Industry

Established Date

10/11/2018

Listing Date

11/07/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

493

Fiscal Year Ends

12-31

Website

www.centogene.com

Security Type

Common stock

Office address

Am Strande 7, 18055 Rostock, Germany

Business

Introduction

Centogene N.V. was incorporated under the laws of the Netherlands on October 11, 2018. The company provides data-driven answers for patients, physicians and pharmaceutical companies with rare and neurodegenerative diseases. The company combines multi-omics technology with CENTOGENE Biodatabank to enable comprehensive analysis to guide precision medicine. The company's unique approach enables rapid and reliable diagnosis for patients, supports physicians to more accurately understand disease states, and accelerates and reduces the risk of targeted drug discovery, development and commercialization. The company's business includes providing solutions for physicians and their patients as well as biopharmaceutical companies, including through partnerships with contract research organizations.

Company Financials

EPS

CNTG has released its 2022 Q2 earnings. EPS was reported at -0.47, versus the expected -0.4, missing expectations. The chart below visualizes how CNTG has performed over recent quarters, highlighting trends in earnings surprises.